Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles
Authors
Reichstetter, SandraCastillo, Gerardo M.
Rubinstein, Israel
Nishimoto-Ashfield, Akiko
Lai, Manshun
Jones, Cynthia C.
Banerjee, Aryamitra A.
Lyubimov, Alex
Bloedow, Duane C.
Bogdanov, Alexei A. Jr.
Bolotin, Elijah M.
UMass Chan Affiliations
Department of RadiologyDocument Type
Journal ArticlePublication Date
2013-03-01Keywords
AnimalsBlood Pressure
Drug Carriers
Excipients
Female
Humans
Mice
Mice, Inbred BALB C
Micelles
Vasoactive Intestinal Peptide
dosage
Vasodilator Agents
Medicinal and Pharmaceutical Chemistry
Other Pharmacy and Pharmaceutical Sciences
Radiology
Metadata
Show full item recordAbstract
PURPOSE: To determine and compare pharmacokinetics and toxicity of two nanoformulations of Vasoactive Intestinal Peptide (VIP). METHODS: VIP was formulated using a micellar (Sterically Stabilized Micelles, SSM) and a polymer-based (Protected Graft Copolymer, PGC) nanocarrier at various loading percentages. VIP binding to the nanocarriers, pharmacokinetics, blood pressure, blood chemistry, and acute maximum tolerated dose (MTD) of the formulations after injection into BALB/c mice were determined. RESULTS: Both formulations significantly extend in vivo residence time compared to unformulated VIP. Formulation toxicity is dependent on loading percentage, showing major differences between the two carrier types. Both formulations increase in vivo potency of unformulated VIP and show acute MTDs at least 140 times lower than unformulated VIP, but still at least 100 times higher than the anticipated highest human dose, 1-5 mug/kg. These nanocarriers prevented a significant drop in arterial blood pressure compared to unformulated VIP. CONCLUSIONS: While both carriers enhance in vivo residence time compared to unformulated VIP and reduce the drop in blood pressure immediately after injection, PGC is the excipient of choice to extend residence time and improve the safety of potent therapeutic peptides such as VIP.Source
Pharm Res. 2013 Mar;30(3):670-82. doi: 10.1007/s11095-012-0904-4. Epub 2012 Dec 7. Link to article on publisher's siteDOI
10.1007/s11095-012-0904-4Permanent Link to this Item
http://hdl.handle.net/20.500.14038/48605PubMed ID
23224976Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1007/s11095-012-0904-4